Citations

Clear

3042 citation(s) found for "Kumar, S".

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, Michael, Hartmann, Sylvia , Eich, Hans Theodor, Savage, Kerry J. , Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A., Vega, Francisco, Alomari, Mohammed , Zhang, Xiaoyin , Collins, Graham P., Advani, Ranjana H, Kumar, Priyadarshini , Wirth, Andrew, Tsang, Richard, Smith, SD, Hendrickson, Peter G. , Hopkins, David, McKay, Pamela, Ng, Andrea K. , Koenig, Julie L. , Sakthivel, Gukan, Baron, Jonathan A, Roberts, Kenneth B. , Gao, Sarah, Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alexander George, Ricardi, Umberto, Sridhar, Akshay, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Shah, Nimish, Osborne, Wendy , Henry, Michael, Chang, Isabela , Halperin, Daniel, Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Bernadette , Penn, Anthony, Reeves, Marie, Terezakis, Stephanie A, Pepa, R Della, Picardi, Marco, Kirova, Youlia, Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Ku, Matthew , Hamad, Nada, Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael, Marconi, Tamara , Viiala, Nicholas , Palese, Monica , Kelly, Kara M, Borchmann, P, Hoppe, Richard T. , Advani, Ranjana H. , Hopkins, David , Baron, Jonathan , Vega, Francisco , Kumar, Priyadarshini , Dickinson, Michael , Smith, Sonali M , McKay, Pamela , Koenig, Julie , Casulo, Carla , Al Kendi, Jalila , Levis, Mario , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S , Hawkes, Eliza , Lee, Denise , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Salvaris, Ross , Ku, Matthew , Hamad, Nada , Tedjaseputra, Aditya , Shankar, Ananth , Maurer, Matthew , Natkunam, Yasodha , Hoppe, Richard T , Binkley, Michael Sargent , Savage, Kerry J , Advani, Ranjana H , Hopkins, David , Baron, Jonathan , Eichenauer, Dennis A , Flerlage, Jamie E , Fuchs, Michael, Eich, Hans Theodor, Hodgson, David C. , Skinnider, Brian, Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Alomari, Mohammed, Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , Constine, Louis S , Casulo, Carla , Plastaras, John Peter , Balogh, Alexander G., Levis, Mario , Ricardi, Umberto , Sridhar, Akshay, Shah, Nimish , Pickard, Keir , Blazin, Lindsay , Henry, Michael, Smith, Christine M. , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Northend, Michael , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Hamad, Nada , Gilbertson, Michael , Maurer, Matthew J. , Natkunam, Yasodha , Kelly, Kara M. , Borchmann, Peter , Binkley, Michael S.

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5338-5347

10.1182/bloodadvances.2026020012 | PMID 41979337 Get It

Abstract We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.
Incidence of infective endocarditis following surgical or transcatheter mitral valve repair or replacement: a systematic review and meta-analysis
Vibhishanan, Jonathan , Zorman, Mark , Malik, Basimah T, Coronelli, Marco , Kumar, Akshaya, Hampshire, Jonathan , Heylen, Katherine, Choksey, Anurag , Eastwick-Jones, Kate , Newton, James D. , Prendergast, B, Cahill, T, Zorman, Mark J , Dawkins, Sam , Prendergast, Bernard , Cahill, Thomas J.

Mayo Clinic

European Heart Journal - Valvular and Structural Heart Disease | April 13, 2026 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/ehjvshd/xwag030 Get It

Abstract Aims Infective endocarditis (IE) is a serious and potentially fatal complication of mitral valve (MV) intervention. There are limited data comparing the incidence of IE after MV repair compared with bioprosthetic MV replacement. The aim of this study was to analyse the incidence and timing of IE after MV repair compared with bioprosthetic valve replacement, in both surgical and transcatheter patient populations. Methods and results A literature search of Medline, Embase, and Cochrane Library (January 2000—September 2025) was conducted. Pooled IE incidence rates were derived using random-effects models. Eighty-two studies (80 939 patients, total follow-up 350 252 patient-years) were included. The overall incidence rate of IE was 0.97 per 100-patient-years (95% confidence interval [CI] 0.71–1.34). IE was more common after surgical MV replacement (SMVR) than surgical MV repair (SMVr): incidence rate 0.93 (95% CI 0.41–1.81) vs 0.39 (95% CI 0.25–0.62) per 100-patient-years, incidence rate ratio (IRR) 2.34 (95% CI 1.06–5.18), P = .035. The incidence of IE after transcatheter MV replacement (TMVR) was comparable to transcatheter MV repair (TMVr) (2.88 [95% CI 1.91–4.33] vs 1.70 [95% CI 0.84–3.43] per 100-patient-years), IRR 1.56 (95% CI 0.73–3.34), P = .250. The cumulative incidence of IE following SMVR was significantly higher than following SMVr at 1- and 2-years post-procedure, but not at 6 months. Conclusions IE is an infrequent complication of mitral valve intervention. The incidence of IE following SMVR is significantly higher than following SMVr, while the incidence of IE following TMVR is numerically but not significantly higher than following TMVr. Reducing IE risk after mitral intervention is a clinical and research priority.
Diagnosis and management of immune effector cell–associated enterocolitis after ciltacabtagene autoleucel
Lim, Kenneth J C , Lee, Hee Eun , Chen, Zongming Eric, Bledsoe, Adam C. , Parrondo, Ricardo , Chhabra, Saurabh , Dooley, Katharine , Corraes, Andre De Menezes Silva , Gertz, Morie A. , Hwa, Y., Stephens, Haily, Kapoor, Prashant , Tan, Melinda S.Y., Kourelis, Taxiarchis , Warsame, Rahma , Yadav, Udit , Wiedmeier-Nutor, Julia Erin, Geyer, Susan, Kumar, Shaji , Chowla, Navreet , Lin, Y., Bledsoe, Adam C , De Menezes Silva Corraes, Andre , Gertz, Morie A , Hwa, Lisa, Cook, Joselle M , Binder, Moritz , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier-Nutor, Erin, Fonseca, Rafael , Kumar, Shaji K , Chowla, Navreet , Parrondo, Ricardo D , Chhabra, Saurabh , Lim, Kenneth J C , Stephens, H. J. B., Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Geyer, Susan M. , Ailawadhi, Sikander , Fonseca, Rafaël

Mayo Clinic

Blood Advances | April 10, 2026 | Volume: 10 | Issue: 13 | Pages: 4495-4507

10.1182/bloodadvances.2025018853 | PMID 41961998 Get It

Abstract Immune effector cell–associated enterocolitis (IEC-EC) has been observed after ciltacabtagene autoleucel (cilta-cel [Carvykti]) chimeric antigen receptor T-cell (CAR-T) therapy. It is associated with dismal outcomes and is poorly characterized. Here, we examined its clinical features, risk factors, and proposed management strategies. Among the 229 consecutive patients who received cilta-cel at Mayo Clinic, 9 (3.9%) presented with a nonresolving, nonbloody, grade 3 diarrhea, often requiring prolonged total parenteral nutrition. Gastrointestinal coinfections were seen in most patients. Median time from CAR-T infusion to symptom onset was 85 days (range, 35-166), and there appeared to be a latency from symptom onset to endoscopic evaluation. Histopathology findings resembling a graft-versus-host disease pattern of mucosal injury were most seen on duodenal biopsies, whereas 2 cases had patterns akin to a T-cell lymphoproliferative disorder (1 CD4+ and 1 CD8+). Independent associated factors for IEC-EC included high-risk disease as defined by the International Myeloma Society and International Myeloma Working Group, prolonged cytokine release syndrome, and antecedent delayed neurotoxicity. Response to first-line therapy comprising IV or oral corticosteroids, bile acid sequestrants, IV immunoglobulin, and antimicrobial-directed therapy was poor, with no durable responses. Biologic therapy appeared to induce durable responses in 3 of the 5 patients (2/2 vedolizumab; 1/3 infliximab); none of the responders had gastrointestinal coinfection. Early gastroenterology input for endoscopic evaluation with the inclusion of duodenal biopsy is a key component for diagnosis. Early institution of biologic therapy after failure of a short course of corticosteroids should be considered.
Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis
Steinhardt, Maximilian , Muchtar, Eli , Kourelis, Taxiarchis , Warsame, Rahma , Mauermann, Michelle Lynn, Buadi, Francis K. , Dingli, David, Leung, Nelson , Cook, Joselle , Go, Ronald S., Hayman, Suzanne R. , Gonsalves, Wilson I, Kapoor, Prashant , Zanwar, Saurabh , Hellou, Tamer , Tan, Melinda S.Y., Halawi, Houssam, Fonder, A C, Hobbs, Miriam, Abdallah, Nadine , Lin, Y., Siddiqui, Mustaqeem, Kyle, R., Einsele, Hermann, Rajkumar, S Vincent, Kumar, Shaji , Steinhardt, Maximilian , Binder, Moritz , Hellou, Tamer , Fonder, Amie , Abdallah, Nadine H , Siddiqui, Mustaqeem A , Kortüm, Martin , Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Leung, Nelson , Muchtar, E , Buadi, Francis K , Cook, Joselle M , Mauermann, Michelle L. , Dingli, David , Go, Ronald S. , Gonsalves, Wilson I. , Binder, Moritz , Halawi, Houssam , Siddiqui, Mustaqeem , Kortüm, K. Martin , Einsele, Hermann , Rajkumar, S. Vincent , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

Blood Advances | April 9, 2026 | Volume: 10 | Issue: 11 | Pages: 4009-4019

10.1182/bloodadvances.2026019722 | PMID 41954624 Get It

Abstract Gastrointestinal (GI) involvement is a clinically relevant but undercharacterized manifestation of systemic light chain amyloidosis (AL). We aimed to define the clinical spectrum, histologic patterns, and outcomes of symptomatic GI involvement in AL. We retrospectively analyzed 4396 patients with AL from 2010 to 2024, of whom 521 (11.9%) had provider-attributed symptomatic GI involvement; 66% had biopsy-proven GI AL. Symptoms most commonly included early satiety (61%), bowel irregularities (58%), nausea (35%), abdominal pain (28%), and dysphagia (23%). Autonomic neuropathy was frequent (43% clinician attributed; 23% via autonomic reflex testing) and contributed to dysmotility-related symptoms, often without GI biopsy positivity. Among 747 GI biopsies, mucosal infiltration predominated (71%) and was associated with bleeding (22% vs 9%), cachexia, and inferior survival, whereas vascular involvement was associated with lower bleeding risk. Combined involvement of mucosa, submucosa, and vessels conferred the worst prognosis (median overall survival [mOS], 2.4 vs 5.1 vs 7.8 years for 3 vs 2 vs 1 layer); mOS was 6.8 years and was primarily driven by cardiac stage and hematologic response (very good partial response [VGPR] or better: hazard ratio, 0.20; 95% CI 0.13-0.32), with more favorable outcomes in patients with isolated GI involvement. Cachexia and persistent diarrhea were the main drivers of morbidity, need for nutritional support, and GI-related mortality (odds ratio, 2.7 for the combined end point). GI bleeding rarely recurred after achieving VGPR or better. Overall, mucosal involvement, cachexia, and dysmotility define clinically meaningful GI AL and support systematic assessment of autonomic dysfunction as well as evaluation of the need for nutritional support as a GI-specific end point for AL trials.
Psychological and Economic Burden on Caregivers in State-funded Pediatric Cochlear Implantation in South India – A Pilot Study
Kumar, Nishant , Samantray, Vineeth Ranjan, Magendiran, Nisha, John, Mary, Syed, Kamran Asif , John, Mary

Mayo Clinic

Current Medical Issues | April 8, 2026 | Volume: 24 | Issue: 2 | Pages: 135-140

10.4103/cmi.cmi_89_25 Get It

Background: Although cochlear implant surgery, along with subsequent speech therapy, is the gold standard for rehabilitating children with severe to profound hearing loss, it is an expensive process. The motivation and involvement of caregivers play a crucial role in achieving successful outcomes following implantation. However, there is a lack of research in India examining the specific challenges faced by caregivers in this context. This pilot study was designed to explore and assess the burden experienced by caregivers of children who have undergone cochlear implantation. Materials and Methods: A pilot observational study was conducted at a tertiary hospital in South India, involving children with bilateral severe to profound hearing loss. The study included children who underwent cochlear implantation and subsequent auditory rehabilitation through the state comprehensive health insurance scheme. Caregivers were interviewed using a semi-structured questionnaire, and their responses were evaluated using the social burden scale and the caregiver burden scale. Results: Twenty cochlear implantees were included in the study. On the social burden scale, 26% of caregivers reported experiencing a severe overall burden, while 71% indicated a moderate burden. According to the caregiver burden scale, most caregivers experienced a mild-to-moderate burden in the emotional domain, whereas the physical, social, and financial domains were associated with low-to-mild levels of burden. Conclusions: Caregivers of cochlear implantees experience a significant degree of emotional and social burden. Therefore, enhancing both financial and psychological support for caregivers is essential. Such improvements will contribute to more effective and comprehensive hearing rehabilitation programs.
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure
Steinhardt, Maximilian , Muchtar, Eli , Kourelis, Taxiarchis , Warsame, Rahma, Buadi, Francis K. , Dingli, D., Leung, Nelson , Cook, Joselle , Go, Ronald S. , HAYMAN, Suzanne, Kapoor, Prashant , Zanwar, Saurabh , Hellou, Tamer , Fonder, Amie , Hobbs, Miriam, Abdallah, Nadine , Lin, Y., Siddiqui, Mustaqeem, Kyle, R., Kortüm, Martin K., Kumar, Shaji , Dingli, David , Dispenzieri, Angela , Steinhardt, Maximilian , Muchtar, E , Kourelis, Taxiarchis , Buadi, Francis K , Dingli, David , Leung, Nelson , Cook, Joselle M , Go, Ronald S , Gonsalves, Wilson , Kapoor, Prashant , Zanwar, Saurabh S , Binder, Moritz , Hellou, Tamer , Abdallah, Nadine H , Lin, Yi , Siddiqui, Mustaqeem A , Kortüm, Martin , Einsele, Hermann , Rajkumar, S Vincent , Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Warsame, Rahma , Hayman, Suzanne R. , Gonsalves, Wilson I. , Binder, Moritz , Siddiqui, Mustaqeem , Kortüm, K. Martin , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

No container title available | April 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9227260/v1 | PMID 41994108 Get It

Abstract Systemic light chain amyloidosis (AL) arises from monoclonal immunoglobulin light chains, but determinants of progression from precursor states remain poorly defined. In a cross-sectional cohort comprising 1950 systemic AL patients diagnosed 2010-2024, 258 (13.2%) patients with a previously diagnosed plasma cell disorder (PCD) were compared to patients with no prior PCD diagnosis. Patients with monoclonal gammopathy of undetermined signficance (MGUS) and smoldering multiple myeloma (SMM) in the former group had lower difference between involved and uninvolved FLCs (dFLC), higher M-protein, and lower rates of t(11;14) at AL diagnosis. Patients developing AL from SMM had a shorter time to AL (median 34.2 versus 61.3 months) and higher dFLC (median 28.9 versus 11.0 mg/dl) compared to those from MGUS. Patients developing AL after known multiple myeloma (MM) or lymphoplasmacytic lymphoma (LPL) commonly lacked deep hematologic response before AL (≤ very good partial response in 78% of MM, 100% of LPL patients). We additionally studied longitudinally followed cohorts of 3,966 MGUS and 426 (SMM) patients with longitudinal FLC measurements and matched follow-up, in which 1.8% of MGUS and 7.2% of SMM patients developed AL. Those patients who developed AL showed markedly higher dFLC at MGUS/SMM diagnosis and more frequent λ restriction and rates of t(11;14). Higher dFLC was associated with progressively earlier AL development; a 10% cumulative risk occurred at 20 months for patients with a dFLC >80 mg/dL but was not reached if dFLC <10 mg/dL at an estimated median follow-up of 86 months. In multivariable analysis, dFLC >6.4 mg/dL (HR 11.3) and λ isotype (HR 3.6) independently predicted AL, whereas heavy chain secretion was associated with lower risk (HR 0.2 for IgG). These findings indicate that AL risk is primarily driven by cumulative light chain exposure, refining our knowledge of AL pathophysiology and providing guidance for follow-up of patients with elevated dFLC.
XACT‐guided interventional procedures: A feasibility study
Yan, Yuchen , Pandey, Prabodh Kumar , Xu, Yifei , Xiang, Shawn (Liangzhong), Sun, Leshan, Sun, Leshan , Abi‐Jaoudeh, Nadine , Wang, ‪Zhehui , Xiang, Shawn

Mayo Clinic

Medical Physics | April 6, 2026 | Volume: 53 | Issue: 4 | Pages: No page available

10.1002/mp.70401 | PMID 41937299 Get It

Abstract Background X‐ray Induced Acoustic Computed Tomography (XACT) is an emerging imaging technique that provides 3D volumetric images from a single projection by detecting X‐ray‐induced acoustic (XA) waves with ultrasound (US) transducers. Unlike MRI or CT, XACT enables real‐time 3D imaging without long acquisition times, 2D limitations, or motion artifacts from mechanical rotation. Furthermore, when integrated with conventional pulse‐echo US through time‐sequenced operation, XACT provides complementary soft‐tissue contrast, establishing it as a promising platform for dynamic interventional radiology (IR) guidance. Purpose This study aims to evaluate the feasibility of XACT as a novel imaging tool for IR, specifically for guiding needle placement and monitoring contrast agent dynamics. Methods We developed a 3D XACT imaging system equipped with a 256‐element 2D matrix array and a portable X‐ray tube to visualize needle insertion and contrast agent dynamics. To capture both needle position and soft tissue anatomy, we integrated a dual‐modality system combining XACT with pulse‐echo US using a 128‐element linear US array. Experiments were conducted on both tissue‐mimic phantoms and soft tissue samples. GPU‐accelerated algorithm has been developed for 3D XACT image reconstruction. Results The results demonstrate the 3D capabilities of XACT imaging for interventional procedures, including monitoring of needle placement and tracking of contrast agent dynamics. The imaging speed reached up to 3∼4 s per frame, constrained by the repetition rate of the X‐ray source and signal to noise ratio. The dual‐modality approach provided clear visualization of the needle's position and the surrounding soft tissue structures, achieving imaging resolution around 2 mm. Conclusions This study demonstrates that XACT imaging is feasible to be used for IR. Its 3D imaging capability with faster imaging speed would be an alternative to cone beam CT and its capability to combine US imaging will provide richer information for soft tissue
Targeting the DNA damage repair protein RAD51 alters fibroblast metabolism and enhances apoptosis in pulmonary fibrosis
Sharma, Arun K., Schaefbauer, Kyle, Ma, Lina , Koenitzer, Jeffrey R. , Schaefbauer, Kyle J., Maurya, Rahul Kumar , Limper, Andrew H. , Choudhury, Malay

Mayo Clinic

No container title available | April 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.01.715935 | PMID 41959281 Get It

Summary Background Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by aberrantly activated, apoptosis-resistant profibrotic lung (myo)fibroblasts. Prior research has demonstrated that lung fibroblasts from patients with IPF exhibit resistance to DNA damage, suggesting that this behavior contributes to their persistent survival and continuous proliferation. We propose that elevated levels of the DNA damage repair protein RAD51 regulate myofibroblast activation and apoptosis and provide a potential therapeutic target to impede fibrosis progression. Methods Human lung fibroblasts were transfected with siRNA against RAD51 or treated with RAD51-specific inhibitor B02 and markers of fibrosis, DNA damage, apoptosis, metabolic reprogramming, and mitochondrial dynamics were assessed. The preclinical efficacy of B02 was evaluated in human precision cut lung slices (PCLS) and in a mouse model of pulmonary fibrosis. Findings RAD51 expression was significantly upregulated in the lungs and lung fibroblasts of IPF patients. Knockdown or inhibition of RAD51 in fibroblasts reduced profibrotic marker expression, suppressed mTORC1 signaling and mitochondrial function, and increased apoptosis susceptibility. Pharmacological inhibition of RAD51 shifted the profibrotic phenotype towards a fibrosis-resolving state in human and mouse PCLS, and in a bleomycin-induced mouse model of lung fibrosis. Interpretation The inhibition of RAD51 exerts therapeutic benefits in lung fibrosis by promoting apoptosis. Our findings identify that inhibiting RAD51 with B02 in fibroblasts impairs DNA repair and induces metabolic reprogramming, making it a potential therapeutic target. Research in context Evidence before this study Pulmonary fibrosis (PF) is characterized by excessive fibroblast activation and subsequent deposition of extracellular matrix (ECM) proteins, which ultimately disrupt normal lung architecture. A significant contributing factor to the pathogenesis of pulmonary fibrosis is the presence of fibroblasts that are resistant to apoptosis, preventing normal wound healing. Recent studies highlight the DNA repair protein RAD51 as effective in protecting fibroblasts from death induced by chemotherapy and ionizing radiation. These finding suggested that RAD51 could have a role in fibroblast activation and apoptosis resistance in pulmonary fibrosis. Added value of this study We demonstrated that RAD51 is important for maintaining apoptosis-resistant fibrotic fibroblasts and their metabolic abnormalities. Our findings indicated that TGFβ-mediated upregulation of RAD51 reduces DNA damage, activates multiple pathways related to fibroblast activation and proliferation, and induces metabolic reprogramming, ultimately regulating apoptosis. Mechanistically, RAD51 inhibition enhanced p53 acetylation at lysine 120 and upregulated the expression proapoptotic proteins PUMA/BAK in mitochondria, promoting apoptosis. Pharmacological inhibition of RAD51 using the specific inhibitor B02 during the fibrotic phase of experimental lung disease effectively ameliorated pulmonary fibrosis. Implications of all the available evidence Our findings establish that RAD51 plays an important role in the survival of apoptosis-resistant fibrotic fibroblasts. We propose that reducing RAD51 expression leads to the metabolic reprogramming of activated fibroblasts, resulting in decreased mitochondrial respiration, reduced ATP levels, and diminished glycolysis or glutaminolysis. These observations suggest that targeting energy metabolism through RAD51 inhibition could be a viable strategy to enhance apoptosis, thereby creating a therapeutically targetable pathway in fibrotic cells. These findings highlight the potential of RAD51 as a therapeutic target for the treatment of IPF.
Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer
Walden, Daniel , Batalini, Felipe , Eslinger, Cody , Nakamura, Y., Krueger, Andrew T., Deshmukh, Sachin Kumar , Yamanaka, Kazunori, Wu, Christina, Sonbol, Mohamad Basam, Xiu, Joanne, Strickler, John, Ahn, Daniel, Muro, Kei, Yoshino, Takayuki, Bekaii-Saab, Tanios, Sonbol, Mohamad Bassam , Wu, Christina , Nakamura, Yoshiaki , Nakamura, Yoshiaki , Wu, Christina , Sonbol, Mohamad B , Strickler, John H , Borad, Mitesh J , Ahn, Daniel H , Muro, Kei , Yoshino, Takayuki , Bekaii-Saab, Tanios S , Batalini, Felipe , Wu, Song , Xiu, Joanne , Strickler, John H. , Borad, Mitesh J. , Muro, Kei , Yoshino, Takayuki , Bekaii‐Saab, Tanios

Mayo Clinic

JCO Precision Oncology | April 3, 2026 | Volume: 10 | Issue: 4 | Pages: No page available

10.1200/po-25-00452 | PMID 41931743 Get It

PURPOSE Homologous recombination deficiency (HRD) is a key determinant of sensitivity to DNA-damaging agents; however, its genomic characterization in colorectal cancer (CRC) remains limited. This study investigated whether low RNA expression of homologous recombination (HR) genes identifies patients with metastatic CRC who derive survival benefit from oxaliplatin- or irinotecan-based therapy. METHODS A total of 22,957 metastatic CRC samples were subjected to DNA and RNA sequencing (Caris Life Sciences, Dallas, TX). Patients with microsatellite instability–high or pathogenic HR gene mutations were excluded to define a HR-proficient cohort. Overall survival (OS) was compared between patients with low (bottom 25%) versus high (top 25%) RNA expression of HR genes after oxaliplatin or irinotecan exposure. Validation was performed in the PARADIGM phase III trial cohort (n = 262) of first-line modified fluorouracil, leucovorin, and oxaliplatin-treated patients with available RNAseq data. RESULTS In the discovery cohort, low expression of core HR genes correlated with significantly longer OS after oxaliplatin or irinotecan exposure, specifically RAD51 (43.0 v 36.3 months; P < .005) and BLM (42.9 v 34.2 months; P < .005). Similar associations were observed for RAD51 (28.1 v 22.9 months; P = .02) and BLM (29.1 v 23.2 months; P < .005) in irinotecan-treated patients. In the PARADIGM validation cohort, low BLM expression was associated with improved OS (41.5 v 22.4 months; HR = 0.52; P = .002), whereas RAD51 showed a favorable but nonsignificant trend. These findings remained significant after adjustment for treatment arm, tumor sidedness, and metastatic burden. CONCLUSION Low BLM RNA expression is associated with improved survival after treatment with DNA-damaging agents, whereas low RAD51 expression shows a favorable but nonsignificant trend. These findings are exploratory and suggest that RNA-based HR gene expression may warrant further investigation as a potential prognostic biomarker in metastatic CRC.
Abstract 6307: Feasibility of a survivorship app for black prostate cancer survivors: Results from a 12-week mHealth pilot study
Kumar, Gaurav, Ghasemi, Parisa , Zhao, Yan D., Dwyer, Kathleen, Kaninjing, Ernie, Young, Mary Ellen , Sabrina, Dickey, Bolajoko, Opeyemi , Ogunsanya, M., Dwyer, Kathleen , Kumar, Gaurav , Nagykáldi, Zsolt , McIntosh, Andrew G. , Dickey, Sabrina L. , Morton, Daniel J. , Kendzor, Darla E. , Ogunsanya, Motolani E.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 6307-6307

10.1158/1538-7445.am2026-6307 Get It

Abstract Introduction: Black prostate cancer (CaP) survivors experience unique quality-of-life (QoL) and recovery challenges after treatment compared with their White counterparts. Smartphone-delivered mobile health interventions offer promising avenues for symptom tracking and lifestyle changes; but their feasibility, user engagement, and acceptability in this population remain unclear. This study assessed the feasibility, engagement, and preliminary impact of the Survivorship App for Ethnically Diverse Black Prostate Cancer Survivors (SAFE-CaPS), designed to improve self-monitoring behaviors and health outcomes. Methods: Nine Black CaP survivors (seven U.S.-born, one African-born, and one Caribbean-born) participated in a 12-week pilot study of SAFE-CaPS. The app provided daily prompts for symptoms (pain, sleep, fatigue, sexual function, anxiety, depression) and behavior tracking (physical activity, diet), brief self-management support, and physician alerts for severe symptom reports. Mental health (GAD-7 and PHQ-9) and QoL (FACT-P) were assessed at baseline and after 12 weeks. Feasibility was evaluated based on adherence rates (i.e., ≥70% of daily diary entries). Engagement and acceptability were assessed via app analytics and qualitative interviews on usability and cultural relevance. Participants were compensated up to $125 via Greenphire ClinCard. Surveys were analyzed with SPSS v29, and interviews with Atlas.ti v23. Results: Participants’ median age at diagnosis was 56 years; six had a positive family history of CaP, and four had undergone radical prostatectomy. Four participants met the feasibility threshold, and eight completed the study. Most daily entries reflected mild pain, fatigue, bowel and urinary issues, and generally good sleep. Several participants frequently reported severe sexual dysfunction, and most diary responses indicated &lt;20 minutes of physical activity per day. Fruit/vegetable intake was low, with about half of daily responses showing 1-2 servings. At baseline, eight participants had minimal anxiety, while five had moderate depression. Overall, QoL improved from week 1 to week 12 in physical, emotional, and functional well-being, while social well-being declined over time. Interviews emphasized the app’s user-friendly design, ease of navigation, and acceptability as key strengths, with several participants highlighting its simplicity and ease of use, with recommendations to reduce repetitive items and address minor technical issues. Conclusions: SAFE-CaPS was feasible and well accepted. Sexual dysfunction, low physical activity, and moderate depression emerged as key concerns, heightening the need for integrated mental health, activity support, and stronger engagement strategies in future mHealth interventions. Citation Format: Gaurav Kumar, Parisa Ghasemi, Yan D. Zhao, Zsolt Nagykaldi, Kathleen A. Dwyer, Andrew G. McIntosh, Ernie Kaninjing, Mary E. Young, Dickey Sabrina, Daniel Morton, Opeyemi Bolajoko, Darla E. Kendzor, Motolani Ogunsanya. Feasibility of a survivorship app for black prostate cancer survivors: Results from a 12-week mHealth pilot study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6307.